Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Assets (2016 - 2025)

ImmunityBio (IBRX) has disclosed Current Assets for 12 consecutive years, with $314.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 70.58% to $314.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $314.9 million through Dec 2025, up 70.58% year-over-year, with the annual reading at $314.9 million for FY2025, 70.58% up from the prior year.
  • Current Assets for Q4 2025 was $314.9 million at ImmunityBio, down from $329.5 million in the prior quarter.
  • The five-year high for Current Assets was $334.3 million in Q4 2021, with the low at $66.8 million in Q2 2023.
  • Average Current Assets over 5 years is $184.5 million, with a median of $173.9 million recorded in 2024.
  • The sharpest move saw Current Assets crashed 57.95% in 2022, then soared 263.38% in 2024.
  • Over 5 years, Current Assets stood at $334.3 million in 2021, then plummeted by 57.95% to $140.6 million in 2022, then surged by 109.2% to $294.1 million in 2023, then crashed by 37.23% to $184.6 million in 2024, then surged by 70.58% to $314.9 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $314.9 million, $329.5 million, and $208.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.